25 January 2019 in Arthritis Care & Research
20 July 2012 in Rheumatology International
24 April 2018 in Arthritis Care & Research
11 December 2014 in Rheumatology
S ir , The leading causes of AA amyloidosis are mainly chronic inflammatory diseases such as RA and JIA, however, FMF is responsible for >60% of patients with AA amyloidosis in Turkey [ 1 , 2 ]. Although colchicine seems effective in the prevention of amyloidosis, no established treatment protocol exists for amyloidosis. There is evidence showing the effectiveness of some biologic treatments, including anti-TNF agents and IL-1 antagonists.
5 May 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Background&Aim: Idiopathic granulomatous mastitis is a rare, benign inflammatory disease of breast. There is no general agreement on the appropriate treatment choice. The aim of the study was to investigate the immunosuppressive administer for idiopathic granulomatous mastitis and risk factors related with disease recurrence. The data of 53 patients with idiopathic granulomatous mastitis were evaluated for this cross-sectional retrospective study. Demographic features and clinical characteristics and course of the patients were obtained from file records. The mean age of the patients was 37.2 ± 6.6 years. Fifty-one of 53 patients received immunosuppressive treatment with or without surgery. Forty-seven (88.6%) of the patients received only immunosuppressive treatment without surgery, while 4 (7.54%) patients received immunosuppressive treatment after surgery. Forty-one (77.3%) of 47 patients who had no surgical resection received methotrexate as immunosuppressive treatment. Other 6 (11.3%) patients received azathioprine or corticosteroid treatment. Complete or partial remission was observed in 50 (98%) of 51 patients who received immunosuppressive treatment, while only 1 (2%) patient did not reach remission. No factors were found related with recurrence of disease. Methotrexate seems to be efficient in the treatment of idiopathic granulomatous mastitis and provides drug free remission.
5 January 2018 in International Journal of Rheumatic Diseases